As of close of business last night, Aclaris Therapeutics Inc’s stock clocked out at $1.19, down -3.25% from its previous closing price of $1.23. In other words, the price has decreased by -$0.0400 from its previous closing price. On the day, 531507 shares were traded.
Ratios:
To gain a deeper understanding of ACRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Powell Andrew Kenneth William bought 6,000 shares for $1.25 per share. The transaction valued at 7,500 led to the insider holds 28,863 shares of the business.
Powell Andrew Kenneth William bought 8,500 shares of ACRS for $10,455 on Mar 01 ’24. The Director now owns 22,863 shares after completing the transaction at $1.23 per share. On Oct 23 ’23, another insider, Monahan Joseph, who serves as the Chief Scientific Officer of the company, sold 6,000 shares for $5.08 each. As a result, the insider received 30,460 and left with 129,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 84.40M and an Enterprise Value of -34.28M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.70 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at -1.10 whereas that against EBITDA is 0.30.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $11.12, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 1.2150, while the 200-Day Moving Average is calculated to be 4.4548.
Shares Statistics:
It appears that ACRS traded 1.67M shares on average per day over the past three months and 711.13k shares per day over the past ten days. A total of 70.89M shares are outstanding, with a floating share count of 64.47M. Insiders hold about 9.09% of the company’s shares, while institutions hold 89.14% stake in the company. Shares short for ACRS as of Mar 15, 2024 were 5.12M with a Short Ratio of 3.07, compared to 5.83M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.22% and a Short% of Float of 8.32%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.37, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.08 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.32 and -$1.35 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.82, with 7 analysts recommending between -$0.31 and -$1.49.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.48M, while the lowest revenue estimate was $2.26M, resulting in an average revenue estimate of $5.58M. In the same quarter a year ago, actual revenue was $31.25M, down -82.10% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $6M in the next fiscal year. The high estimate is $7.8M and the low estimate is $2.26M. The average revenue growth estimate for next year is up 7.50% from the average revenue estimate for this year.
